CompanyHealthAi
Superfluid Dx, Inc.
Superfluid Dx is a South San Francisco diagnostics company building a blood-based test for Alzheimer's disease and other neurodegenerative conditions. Its platform isolates cell-free messenger RNA (cf-mRNA) from a single tube of blood and pairs next-generation sequencing with RNA deconvolution and machine-learning analysis to read out organ-level biology - aiming to detect disease years earlier than conventional methods and to guide therapy. The company was formed in late 2023 when WRQ Sciences acquired and renamed Molecular Stethoscope, and is led by Fluidigm co-founder Gajus Worthington alongside Stanford bioengineer and serial founder Steve Quake.
2023Founded
South San FranciscoHQ
Undisclosed (oversubscribed); ~$8.2M total funding reportedSeries A
cf-mrnacell-free mrnaliquid biopsyalzheimers blood testneurodegenerative diagnosticsmolecular diagnostics
